Filtros de búsqueda

Lista de obras de

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

scientific article published on 19 August 2019

Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

artículo científico publicado en 2014

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

artículo científico publicado en 2010

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

artículo científico publicado en 2016

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

scientific article published on 03 June 2019

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

artículo científico publicado en 2002

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial

scientific article published on 19 June 2019

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

artículo científico publicado en 2019

Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma

artículo científico publicado en 2019

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk

artículo científico publicado en 2019

Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

artículo científico publicado en 2020

Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria

artículo científico publicado en 2017

Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study

artículo científico publicado en 2018

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

artículo científico publicado en 2017

Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

artículo científico publicado en 2012

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis

artículo científico publicado en 2018

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

scientific article published on 24 September 2018

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results

artículo científico publicado en 2015

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

artículo científico publicado en 2013

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

artículo científico publicado en 2018

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009

artículo científico publicado en 2017

Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

artículo científico publicado en 2015

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

artículo científico publicado en 2018

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

scientific article published on 11 October 2016

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial

artículo científico publicado en 2016

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

artículo científico publicado en 2016

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda